Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
JournalBlood Neoplasia
Publication statusAccepted/In press - 21 Apr 2024

Cite this